-$0.12 EPS Expected for Galectin Therapeutics Inc. Common Stock (GALT) This Quarter

Share on StockTwits

Wall Street brokerages expect Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) to announce earnings of ($0.12) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectin Therapeutics Inc. Common Stock’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.12). Galectin Therapeutics Inc. Common Stock posted earnings per share of ($0.13) during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.7%. The firm is expected to issue its next earnings report on Tuesday, November 6th.

On average, analysts expect that Galectin Therapeutics Inc. Common Stock will report full year earnings of ($0.46) per share for the current fiscal year, with EPS estimates ranging from ($0.46) to ($0.45). For the next financial year, analysts anticipate that the firm will report earnings of ($1.06) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Galectin Therapeutics Inc. Common Stock.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Several analysts recently issued reports on the stock. ValuEngine raised shares of Galectin Therapeutics Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. BidaskClub raised shares of Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Finally, HC Wainwright lifted their price target on shares of Galectin Therapeutics Inc. Common Stock to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 15th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $6.94.

NASDAQ GALT traded up $0.02 during mid-day trading on Friday, hitting $3.87. The company’s stock had a trading volume of 341,274 shares, compared to its average volume of 724,596. Galectin Therapeutics Inc. Common Stock has a twelve month low of $1.28 and a twelve month high of $9.49. The company has a market cap of $182.83 million, a P/E ratio of -7.90 and a beta of 2.29.

In other Galectin Therapeutics Inc. Common Stock news, CEO Peter G. Traber sold 70,000 shares of Galectin Therapeutics Inc. Common Stock stock in a transaction on Friday, June 8th. The shares were sold at an average price of $5.86, for a total transaction of $410,200.00. Following the transaction, the chief executive officer now directly owns 177,333 shares of the company’s stock, valued at approximately $1,039,171.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jack W. Callicutt sold 46,651 shares of Galectin Therapeutics Inc. Common Stock stock in a transaction on Thursday, May 31st. The stock was sold at an average price of $5.00, for a total transaction of $233,255.00. Following the transaction, the chief financial officer now directly owns 47,911 shares in the company, valued at $239,555. The disclosure for this sale can be found here. In the last three months, insiders sold 1,743,263 shares of company stock valued at $11,905,122. 45.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of GALT. D.A. Davidson & CO. boosted its holdings in Galectin Therapeutics Inc. Common Stock by 6.3% during the 1st quarter. D.A. Davidson & CO. now owns 731,300 shares of the company’s stock worth $3,466,000 after acquiring an additional 43,147 shares during the last quarter. Benchmark Capital Advisors boosted its holdings in Galectin Therapeutics Inc. Common Stock by 19.7% during the 1st quarter. Benchmark Capital Advisors now owns 221,700 shares of the company’s stock worth $1,051,000 after acquiring an additional 36,500 shares during the last quarter. Tibra Equities Europe Ltd purchased a new position in Galectin Therapeutics Inc. Common Stock during the 1st quarter worth $301,000. A.R.T. Advisors LLC boosted its holdings in Galectin Therapeutics Inc. Common Stock by 60.2% during the 1st quarter. A.R.T. Advisors LLC now owns 57,775 shares of the company’s stock worth $273,000 after acquiring an additional 21,704 shares during the last quarter. Finally, LPL Financial LLC purchased a new position in Galectin Therapeutics Inc. Common Stock during the 1st quarter worth $112,000. 11.87% of the stock is currently owned by hedge funds and other institutional investors.

About Galectin Therapeutics Inc. Common Stock

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Read More: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Galectin Therapeutics Inc. Common Stock (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply